ARTBIO is a startup based in the United States, most recent round Series B, 2 tracked investors.
Based in the United States, ARTBIO is a startup founded in 2010. Its most recent tracked round is Series B. Brouky records 2 investors associated with the company.
ARTBIO is a clinical-stage radiopharmaceutical company developing a new class of alpha radioligand therapies (ARTs) to treat various cancers, utilizing the alpha-emitting isotope Pb212 for targeted tumor treatment.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.